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Abstract: Our goal in this chapter is to explore the complex processes of metastasis and why there is a
predisposition for this to occur in the lung. In addition, we aim to describe the incidence of pulmonary
metastases in various contexts and based on the origin of the primary tumor. There are unique characteristics
of the pulmonary system that make metastases more likely to occur in the lung than anywhere else in the
body. Some of these characteristics include receiving the entire cardiac output every minute, having the
densest capillary bed in the body, and being the first reservoir of most lymphatic drainage entering the
venous system. There are multiple postulated routes of metastasis to the pulmonary system including
hematogenous and lymphatic routes with early or late dissemination. The vascularization of pulmonary
metastases is variable and complex, often recruiting supply from bronchial and pulmonary origin. There
are also many biochemical factors in the tumor microenvironment that play a key role in the development
of lung metastases including vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), very late
antigen 4 (VLA-4) and intercellular adhesion molecule 1 (ICAM-1). Studies vary widely in reported rates
of pulmonary metastases due to differences in clinical study design, however, it is commonly accepted that
up to half of autopsies performed on patients who died of malignancy have pulmonary metastases. In a
surgical series describing the incidence of primary cancer types with resected pulmonary metastases the most
common sites were thyroid, colon, breast, genitourinary tract, skin, liver, breast, and adrenal glands.
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Introduction
Pulmonary metastases are a common occurrence in patients
with extrathoracic cancer. Our goal in this chapter is to
explore the complex processes of metastasis and why there
is a predisposition for this to occur in the lung. In addition,
we aim to describe the incidence of pulmonary metastases
in various contexts and based on the origin of the primary
tumor.
Pathophysiology
The process of metastatic spread involves many complex
events. The pathophysiology of pulmonary metastasis
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is initiated with the growth, neovascularization, and
tissue invasion of the primary tumor. Subsequently,
there is detachment of cells from the primary tumor and
hematogenous dissemination where these cells may arrest
and proliferate in capillary beds. After surviving host
defense mechanisms, the tumor cells extravasate into larger
arteries and extend into organs by adhering to the basement
membrane (1). There are many host-factors that must act
in concert for this process to occur, including cell adhesion
molecules, motility, growth and angiogenesis factors and
various cytokines (2,3).
There are unique characteristics of the pulmonary system
that make metastases more likely to occur in the lung than
anywhere else in the body. Schueller et al. describe these
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features well, “The lungs receive the entire cardiac output
every minute. They also have the densest capillary bed
in the body and are the first capillary plexus that most of
the lymphatic drainage meets after entering the venous
system. In addition, the lungs consist of a meshwork of
delicate membranes that easily entrap tumor cells which can
readily draw on nearby oxygenated air for sustenance.” (4).
These characteristics provide an ideal situation and
environment for the cascade of events to occur that lead to
metastases in the lung. The rate of growth of metastases
was studied by Spratt et al. They performed a radiographic
study of 118 patients with untreated pulmonary metastases
and demonstrated, through mathematical calculation and
radiographic correlation, that the rate of growth of the
pulmonary metastases was exponential (5).
There are multiple routes of metastasis to the lung from
extra thoracic tumors. Certain groups of extrathoracic
tumors have characteristic patterns of spread attributed to
the unique and complex series of events that must occur
for metastasis to succeed. The most common route of
metastasis is a hematogenous mechanism. This pattern of
spread is first initiated with detachment of cells from the
primary tumor and hematogenous dissemination of the cells
into pulmonary capillary beds. A minority of these cells
will survive host defense mechanisms and penetrate the
pulmonary interstitium, leading to metastatic growth (6).
It is also possible for the pulmonary vasculature to be
seeded at the same time as dissemination in other capillary
beds such as the liver, bone or brain. In addition, there are
situations where hematogenous spread occurs only after
other capillary beds have been seeded, such as prostate
or breast cancer. Metastatic spread can also occur via
lymphatic channels—regional lymph nodes become the site
of collection, which commonly occurs with endobronchial
metastases (7).
As previously described, pulmonary metastasis is a
complex process of tumor cell dissemination from the
primary tumor to the lungs. There are currently two major
concepts of metastasis that may influence the approach
of clinicians (8). Fidler et al. describes a theory of late
dissemination of metastases. This is postulated to occur
after genetic changes to the primary tumor and surrounding
environment have occurred that are sufficient for migration
and spread (9). A different theory suggests metastasis occurs
via early dissemination. Morgan et al. describes a process of
early shedding of single cancer cells. There is a subsequent
dormant stage where the cells may acquire genetic and
environmental alterations that trigger proper metastasis and

lead to delayed recurrence (10). Both theories of metastasis
may occur separately or together within different tumor
types and individuals—rendering the genetic composition
and characteristics of pulmonary metastases unique and
complex to treat.
For lung metastases to grow, adequate nutrition is
needed via a viable blood supply. In the lung, there are
three possible routes: bronchial circulation, pulmonary
circulation, or both. The route of blood supply to the
metastases is important as it can be a means of therapeutic
intervention. Historically, it was held that most lung tumors
are supplied by bronchial circulation and that pulmonary
“neovascularization” did not occur (11-13). However,
Milne et al. conducted a computer topographic angiography
study of resected human lungs with pulmonary metastases
of varying origin which demonstrated that angiogenesis
does occur. In addition, there was a pulmonary circulation
component in all metastases usually supplying the lateral
portion of the tumor (14). The vascularization of pulmonary
metastases is variable and complex, often recruiting supply
from bronchial and pulmonary origin.
Interestingly, diet may also have a role in tumor growth.
Hayman et al. details a study that has shown how a diet high
in omega-6 fatty acids has been linked to statistically higher
rates of visible lung metastases in mice injected with human
breast cancer cells. As well, omega-3 fatty acids have been
shown to reduce lung metastases in colorectal cancer, breast
carcinoma, and melanoma (15). This is postulated to be
due to influences on gene expression which can affect the
production of various protein factors.
There are many biochemical factors in the tumor
microenvironment that play a key role in the development
of lung metastases. Laboratory studies have shown that
cellular factors such as vascular endothelial growth factor
(VEGF), interleukin-8 (IL-8), platelet-derived endothelial
cell growth factor (PD-ECGF), and/or basic fibroblast
growth factor (bFGF) play an important role in the tumor
microenvironment (16). As well, tumor cells have a role
in metastatic invasion with very late antigen 4 (VLA-4)
production from hematopoietic progenitor cells. This
production of VLA-4 allows for interaction with fibronectin
in fibroblasts at premetastatic sites (17). Chemokines are
activated by tumor cells through the attraction of immune
cells and tumor cells to the lungs via VEGF-A, tumor
necrosis factor-α (TNF-α), and transforming growth factor–
β (TGF-β) inducing expression of inflammatory chemokines
used for lung invasion (18). Once tumor cells are at the site
of metastasis, they can anchor to the environment through
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Table 1 Incidence and cumulative incidence of pulmonary metastases° in various non-pulmonary cancer type
Tumor type
Osteosarcoma

Incidence at diagnosis (%)*

Cumulative Incidence (%)**

Frequency of metastases restricted
to the lungs (%)***

NA

38–95

NA

Soft tissue sarcoma

66

Renal cell carcinoma

55–75

Testicular cancer

20–30

40–50

<5

NA

12–41

NA

Colorectal cancer

14

2–4

Pancreatic cancer

40

0

37–70

NA

Uterine cancer

5

1

Cervical cancer

10–20

25

Ovarian cancer

28

0

Breast

5

10–15

Head and neck cancer

Hepatocellular cancer

Melanoma

48

70

10

Thyroid cancer

NA

10–25

NA

Adrenocortical cancer

71

Choriocarcinoma

60

NA

Prostate

<1

25

0

Overall

20

20–50

NA

°, pulmonary parenchymal metastases; *, expressed as percentage of patients presenting with the specific tumor type; **, expressed as
percentage of patients with the specific tumor type; ***, expressed as percentage of patients with metastases restricted to the lung (without
metastases elsewhere).

surface expression of intercellular adhesion molecule 1
(ICAM-1) induced be recruited neutrophils (19). Cellular
expression of proteins that enhance anchoring, recruitment
of cells and invasion are necessary for lung metastasis.
Epidemiology
The lung is the most common site for cancer metastases.
In addition, that most common malignant tumors found
in the lung are metastases from extrathoracic tumors
(4,20). Studies vary widely in reported rates of pulmonary
metastases due to differences in clinical study design
such as tumor type, the time period from primary tumor
to pulmonary metastases, and the type and frequency of
imaging used to detect them. This time period can be
significant as it has been shown that pulmonary metastases
have been described up to 15 years after primary cancer
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detection (6). It is commonly accepted that up to half of
autopsies performed on patients who died of malignancy
have pulmonary metastases (21,22). Regardless of the
high amount of reported lung metastases in patients with
cancer, only 15% to 20% develop clinical symptoms such
as cough or nonspecific chest pain from metastases (15).
Van Meerbeeck et al. combined data from multiple autopsy
series to describe the cumulative incidence of pulmonary
metastases for non-pulmonary types of cancer (Table 1) (23).
This shows a high incidence in urogenital and intestinal
origin likely due to the cancer distribution of the
population. Detterbeck et al. conducted a surgical series of
6,732 patients describing the incidence of primary cancer
types with resected pulmonary metastases (Table 2) (24).
These resected metastases were presumed “solitary”
or “unique” by available staging techniques and reflect
a more clinically meaningful distribution of identified
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Table 2 Distribution of primary cancer types in patients with
resected pulmonary metastases in a surgical series of 6,732 patients
Primary cancer type

Distribution (%)

Sarcoma

36

Teratoma

3–37

Head and neck cancer

5–24

Colon cancer

10

Breast cancer

9

Genito-urinary cancer

9

Melanoma

4

Gyncecological cancer

4
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